Physician profile
April Stone
NPI 1306380613
$6,485.16
in general payments reported to CMS, 2019-2025
19 companies · $1,934 in 2025
The $1,934 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $329 · 2022: $1,585 · 2023: $1,282 · 2024: $1,355 · 2025: $1,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,544 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,544.01 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,955.61 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,015.67 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $776.69 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $590.97 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $570.59 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $326.82 | 2022-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $315.41 | 2022-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $233.41 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Corium, LLC | $170.23 | 2023-2025 | Azstarys |
| Allergan, INC. | $148.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $108.15 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $104.89 | 2022-2025 | Rexulti |
| Bausch Health US, LLC | $48.09 | 2022-2024 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $33.04 | 2024 | |
| Alexion Pharmaceuticals, INC. | $23.09 | 2024 | Ultomiris |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $17.90 | 2025 | Loreev Xr |
| Tempus Ai, INC | $17.42 | 2024 | |
| Axsome Therapeutics, INC. | $14.80 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $13.64 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.